Armenta - Striking A Balance Between Sustainability, Welfare and Profitability - A Whole-System Approach.
Armenta developed and commercialized the 1st non-antibiotic treatment for Bovine Mastitis using Acoustic Pulse Technology (APT). Armenta's revolutionary antibiotic-free treatment of mastitis in dairy cattle results in significant udder remedy & higher milk yield within days of therapy. We are fully commercial, targeting a $1b annual market.
Gil Hakim
[email protected]
HaPnina 8
0525263351
https://armentavet.com/
Developed, manufactured, and markets the 1st non-antibiotic treatment for Bovine Mastitis using Acoustic Pulse Technology (APT). Although treated with antibiotics, Bovine Mastitis is the leading cause for losses to the dairy industry accounts for several billions of dollars in annual losses.
Bovine Mastitis affect milk yield, milk quality and increase the risk for culling.
APT is already used in human medicine. It was documented to induce neo-angiogenesis (creation of new blood vessels) , modify of the immune to fight invading bacteria and control the inflammatory response of the target tissue.
By using Acoustic Pulse Technology (APT) udder tissue regeneration and rehabilitation of function is restored, yielding to higher milk production, higher milk quality and lower culling rates leading to high profitability and quick ROI.
Armenta potential market is >$1B annually and the products are commercially available.
APT device is simple to operate, hand-held, mobile and powered by air pressure to allow treatment in every setting.